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Reagent	 Manufacturer	 Catalogue	number	3-aminopropyltriethoxysilane	(APES)	 Sigma	Aldrich	 A3648	Ammonium	persulphate	(APS)	 Sigma	Aldrich	 A3678	Bovine	serum	albumin	(BSA)	 Sigma	Aldrich	 A9647	DAPI	 New	England	Biolabs	 4083S	DNeasy®	Powerclean®	Pro	Cleanup	Kit	 Qiagen	 12997-50	Donkey	serum	 Sigma-Aldrich	 D9663	MinElute™	PCR	Purification	Kit	 Qiagen	 28004	N,	N,	N’,N-Tetramethylethylenediamine	(TEMED)	
Sigma	Aldrich	 T7024	
PAP	Pen	 Sigma	Aldrich	 Z377821		QIAamp	Fast	DNA	Stool	Kit	 Qiagen	 51604	RedTaq®	ReadyMix™	PCR	Reaction	Mix	 Sigma	Aldrich	 R2523	Spinkote	Lubricant	 Beckman	Coulter	 306812	SYBR®	Gold	Nucleic	Acid	Gel	Stain	(10,000x)	 Thermo	Fisher	Scientific	 S11494	SYBR®	Green	JumpStart™	Taq	Readymix™		 Sigma	Aldrich	 S4438	Triton	X-100	 Sigma	Aldrich	 T8787	Vectashield®	Mounting	Medium	 Vector	Laboratories	 H-1000	
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3.3	Antibodies		Antibody	 Manufacturer	 Catalogue	number	 Concentration	 Working	dilution	Alexa	Fluor®	488	donkey	anti-rabbit	IgG	(H+L)	
Invitrogen	 A-21206	 2	mg/ml	 1:500	
Anti-chromogranin	A	
Abcam	 ab15160	 0.355	mg/ml	 1:200	




















3.4	PCR	Primers		16S	rRNA	 	341F_GC	 5’	CGCCCGCCGCGCGCGGCGGGCGGGGCGGGG											CSCGGGGGGCCTACGGGSGGCSGCSG-3’	518R	 5’-ATTACCGCGGCTGCTGG	-3’		








































4.4	Bacterial	16S	rDNA	Extraction		The	tissues	were	defrosted	on	ice.	Each	tissue	was	dissected	down	the	middle	to	expose	the	luminal	contents.	DNA	extraction	was	carried	out	firstly	on	the	luminal	contents	and	then	the	mucosal	layer	using	the	QIAamp	Fast	DNA	Stool	Kit	(Qiagen)	according	to	manufacturers	specifications.	The	following	steps	were	adjusted	for	optimisation:	the	first	heating	step	was	increased	to	95°C	for	30	min.	The	volume	of	proteinase	K	was	increased	to	30 µl.	The	volume	of	supernatant	removed,	and	the	volume	of	Buffer	AL	and	ethanol	added	was	increased	to	400 µl.	The	volume	of	Buffer	ATE	added	to	the	membrane	was	decreased	to	100 µl	and	the	incubation	period	was	increased	to	5	min.						
	4.5	16S	rDNA	Quantitative	Real-Time	Polymerase	Chain	Reaction	(qRT-
PCR)	





	4.6.1	PCR	and	Purification	of	16S	rDNA	for	DGGE		The	DNA	extracted	from	the	mucosal	and	luminal	contents	were	diluted	1:10	in	nuclease	free	H2O,	from	which	100ng	of	DNA	in	9.5 µl	nuclease	free	water	was	prepared	for	each	sample.	A	master	mix	was	prepared	containing	for	each	sample;	12.5 µl	Taq	polymerase,	1 µl	BSA,	1 µl	of	the	forward	and	reverse	universal	16S	rRNA	primers	(table	6).	15.5 µl	of	the	master	mix	was	added	to	each	PCR	reaction.	The	PCR	parameters	were	as	follows:	1	cycle	at	95°C	for	5	min,	29	cycles	of	95°C	for	30	sec,	57°C	for	30	sec,	72°C	for	30	sec,	and	1	cycle	at	72°C	for	5	min.			The	PCR	products	were	purified	using	MinElute	PCR	Purification	Kit	(Qiagen)	and	DNeasy®	Powerclean®	Pro	Cleanup	Kit	(Qiagen)	according	to	manufacturer’s	specifications.	The	following	adjustments	were	made	for	optimisation:	the	volume	of	Buffer	EB	used	in	the	MinElute	Kit	was	decreased	to	20 µl.	In	the	DNeasy®	Powerclean®	Pro	Cleanup	Kit	(Qiagen)	the	volume	of	EB	solution	was	increased	to	20 µl	and	the	incubation	period	was	increased	to	5	min.	The	DNA	concentration	was	quantified	using	NanoDropTM	2000c	Spectrophotometer	(Thermo	Fisher)	and	stored	at	-80°C	until	required.						
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	 Ileum	(villus)	 Ileum(crypt)	 Caecum	 Colon	
3	Month	 ↑	p	=	0.31	 ↑	p	=	0.17	 	 ↓	p	=	0.003	
7	Month	 ↑	p	=	0.17	 ↓	p	=	0.71	 ↑	p	=	0.38	 ↑	p	=0.82	







	 Ileum		(villus)	 Ileum	(crypt)	 Caecum	 Colon	
3	Month	 ↓ p	=	0.63	 ↓	p	=0.61	 			 ↑	p	=	0.52	
7	Month	 ↓	p	=0.21	 ↓	p	=	0.21	 ↓	p	=	0.13	 ↓	p	=	0.44	









	 Ileum	(villus)	 Ileum	(crypt)	 Caecum	 Colon	
3	Month	 ↑	p	=	0.68	 ↑	p	=	0.56	 	 ↑	p	=	0.002	
7	Month	 ↓ p	=	0.40	 ↓	p	=	0.21	 /	p	=	0.99	 ↓	p	=	0.04	
15	Month	 ↓	p	=	0.61	 ↓	p	=	0.25	 ↓	p	=	0.54	 ↑	p	=	0.25		
Table	10:	Summary	of	statistical	analysis	of	EEC	numbers		Average	number	of	EEC’s	per	100	µm	of	villus	height	and/or	crypt	depth	of	the	ileum,	caecum	and	distal	colon	in	three,	seven	and	fifteen	month	WT	and	APP/PS1	mice. ↑	=	increase,	↓	=	decrease,	/	=	no	change	in	APP/PS1	compared	to	WT.	Green	box	indicates	statistically	significant	result.	Black	box	indicates	data	not	collected.					6.4	Microbial	community	diversity	–	qRT-PCR			 	 Ileum	 Caecum	 Colon	
3	month	 Firmicutes	 	 ↑	p	=	0.86	 	
Bacteroidetes	 	 ↓	p	=0.27	 	
7	month	 Firmicutes	 ↓	p	=	0.20	 ↑	p	=	0.92	 ↓	p	=	0.05	
Bacteroidetes	 ↑	p	=	0.33	 ↑	p	=	0.68	 ↑ p	=	0.92	
15	month	 Firmicutes	 ↓	p	=	0.58	 ↓	p	=	0.27	 ↓	p	=	0.80	




	 Ileum	 Caecum	 Colon	
3	Month	 	 p	=	0.04	 	
7	Month	 p	=	0.82	 p	=	0.82	 p	=	0.44	
15	Month	 p	=	0.54	 p	=	0.24	 p	=	0.83			Luminal:		
	 Ileum	 Caecum	 Colon	
3	Month	 	 p	=		0.66	 	
7	Month	 p	=	0.07	 p	=	0.81	 p	=	0.49	





	 Ileum	 Caecum	 Colon	
3	Month	 	 ↑	p	=	0.03	 	
7	Month	 p	=0.69	 p	=	0.38	 p	=	0.58	
15	Month	 p	=	0.56	 p	=	0.52	 p	=	0.91			Luminal:		
	 Ileum	 Caecum	 Colon	
3	Month	 	 p	=	0.85	 	
7	Month	 p	=	0.40	 p	=	0.35	 p	=	0.75	













































Since it has been reported that environmental factors influencing the gut microbiota in neonates can influence disease it is may be required to take precautions in utero. In humans a HFD during pregnancy has been shown to cause a decrease in Bacteroidetes in, which was still apparent at six weeks of age. (Chu et al.,2016). A maternal HFD in the non-human primate Macaca fuscata was shown to induce dysbiosis in the offspring, which at one year of age, the equivalent to three years old in humans, could only be partially corrected post weaning using a low fat diet (Ma et al, 2014). This highlights the potential long-term consequences of maternal diet on the infant gut microbiome, and suggests that diet alterations may have to be made during pregnancy. 	As	previously	discussed	antibiotic	use	can	cause	dysbiosis,	and	the	problem	is	likely	to	be	exacerbated	by	inappropriate	prescribing	and	use	of	antibiotics.	In	2016	the	UK	government	pledged	in	2016	to	half	the	number	of	inappropriate	prescriptions	by	2020	highlighting	the	need	for	education	on	the	detrimental	consequences	to	health	(WWW,	health	media.blog.gov).	In	addition,	AD	will	become	even	more	of	a	global	problem	in	the	future,	with	the	life	expectancy	of	low	economically	developed	countries	increasing.	One	study	in	a	community	of	Ethiopia	found	over	a	third	(35.9%)	of	antibiotic	users	did	not	use	them	appropriately	with	the	majority	terminating	their	course	early.	In	addition,	over	a	third	(36.8%)	acquired	their	antibiotics	without	prescription	(Erku,	Mekuria	&	Belachew,	2017).	This	highlights	the	need	for	education	in	both	high	and	low	economically	developed	countries	to	reduce	antibiotic	use.					7.8	Future	work		Although	we	found	significant	differences	in	the	microbial	profiles	of	APP/PS1	mice	using	qRT-PCR	and	DGGE	techniques,	these	methods	provide	only	a	brief	insight	in	to	the	dysbiosis	in	the	gut.	For	qRT-PCR	we	utilised	phylum	specific	primers,	which	only	provided	information	on	the	higher	taxonomic	levels	and	
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DGGEs	are	only	indicative	of	dysbiosis	and	lack	specificity	as	more	than	one	species	can	be	represented	by	a	single	band	on	the	gradient	gel	(Tabit,	2016).			Future	work	will	require	using	pyrosequencing	to	gain	a	more	in	depth	understanding	of	dysbiosis	at	the	lower	taxonomic	levels.	This	may	help	to	elucidate	the	cause	of	the	downstream	effects	we	observed,	such	as	changes	in	the	colonic	crypt	depth,	EEC	and	goblet	cell	numbers.	Using	pyrosequencing	on	region	specific	mucosal-associated	microbiota	will	also	enable	better	comparisons	to	be	made	with	previous	literature	that	have	used	pyrosequencing	from	faecal	pellet	samples	(Shen,	Liu	&	Ji,	2017).	This	may	determine	the	most	appropriate	method	to	analyse	microbiota	and	may	influence	future	research	by	making	studies	more	accurate	and	comparable.		In	addition	to	pyrosequencing	other	techniques	should	also	be	employed,	such	as	flow	cytometry	and	transmission	electron	microscopy.	This	may	enable	a	more	accurate	representation	of	AD	associated	microbiota	profiles,	as	individual	techniques	used	on	the	same	sample	have	been	shown	to	produce	conflicting	results	(Hugon	et	al.,	2013).		It	would	also	be	interesting	to	investigate	changes	in	the	number	of	Paneth	cells	in	the	ileum	of	fifteen-month	APP/PS1	mice	using	fluorescent	IHC.	We	have	reported	a	decrease	in	the	number	of	goblet	cells	in	the	ileum	and	suggest	this	may	result	in	less	mucus	secreted,	which	could	allow	increased	translocation	of	the	microbiota	and	metabolites	across	the	leaky	gut	barrier.	Since	the	mucus	layer	normally	serves	as	a	barrier	between	the	epithelial	cells	and	microbiota,	it	would	be	interesting	to	see	how	the	population	of	Paneth	cells	is	affected,	and	whether	it	contributes	or	tries	to	reduce	the	pathology.		Metabolic	profiling	using	gas	chromatography	coupled	to	mass	spectrometry	of	microbial	metabolites	in	the	dysbiotic	regions	would	also	be	required	in	future	studies	as	described	by	González-Domínguez,	Garciía-Barrera	&	Gómez-Ariza	(2015).	Since	the	use	of	mucosal	samples	is	unique	to	previous	studies	it	would	be	necessary	to	assess	the	effects	that	mucosal	dysbiosis	has	on	metabolite	
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production	in	the	regions	where	differences	have	been	reported	in	the	APP/PS1	mice.	This	would	provide	a	better	understanding	of	the	consequences	of	dysbiosis	and	how	this	would	impact	the	functioning	of	the	GBA.	Comparing	results	to	previous	metabolomic	studies	that	utilised	faecal	pellets	would	also	provide	a	better	understanding	in	to	the	functionality	of	the	samples	with	regards	to	the	most	appropriate	sample	(Sanguinetti	et	al.,	2018).		In	our	study	we	reported	a	decrease	in	the	number	of	goblet	cells	in	the	villi	and	crypts	of	the	ileum	in	fifteen-month	APP/PS1	mice.	Future	work	would	benefit	from	determining	if	this	results	in	less	mucus	secreted	in	the	ileum,	by	measuring	the	thickness.	Quantification	of	mucus	thickness	has	previously	been	carried	out	using	different	methods	including	a	modified	version	of	the	PAS/AB	stain,	as	described	by	Jordan	et	al.	(1998)	and	using	an	ex	vivo	model	utilising	a	horizontal	perfusion	chamber	and	measuring	mucus	thickness	using	a	micropipette	as	described	by	Gustafsson	et	al.	(2012).	If	a	decrease	in	mucus	production	were	observed,	it	would	be	interesting	to	see	if	translocation	of	the	microbiota	across	the	leaky	gut	is	increased	in	the	ileum.	Fluorescent	in	situ	hybridisation	(FISH)	could	be	used	to	quantify	the	penetrance	of	bacteria	across	the	mucus	and	translocation	across	the	leaky	gut	barrier	in	APP/PS1	mice	using	16S	rRNA	probes	(Johansson	et	al.,	2014).			Future	research	outside	of	this	project	requires	longitudinal	studies	characterising	the	human	gut	microbiota	through	life	in	individuals	who	go	on	to	develop	AD.	The	findings	needs	to	confirm	at	roughly	what	age	that	the	gut	microbiota	is	pivotal	in	determining	whether	an	individual	has	an	increased	risk	of	developing	AD.	This	could	be	accomplished	by	determining	what	age	divergence	between	non-AD	and	AD	microbiota	profiles	occurs.	From	this	it	may	be	necessary	to	identify	a	criteria	and	time	point	at	which	looking	at	an	individual’s	microbiota	profile	would	be	appropriate	in	order	to	identify	the	risk	of	developing	AD.					
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8.	Conclusion		In	this	study	we	utilised	the	APP/PS1	mouse	model	at	three,	seven	and	fifteen-months	old	to	characterise	changes	in	the	mucosal	and	luminal-associated	microbiota	in	specific	regions	of	the	GI	tract	using	qRT-PCR	and	16	rDNA	DGGE.		Changes	in	gut	architecture	and	differences	in	goblet	cell	and	EEC	numbers	were	also	investigated	using	PAS/AB	stain	and	fluorescent	IHC	in	APP/PS1	mice	compared	to	WT	littermates.			To	our	knowledge	this	is	the	first	study	to	investigate	dysbiosis	within	the	mucosal	and	luminal-associated	microbiota	and	at	specific	regions	in	the	GI	tract	in	a	model	of	AD.	The	main	finding	of	this	project	was	that	dysbiosis	in	the	mucosal-associated	microbiota	occurs	in	three-month	APP/PS1	mice	and	is	normalised	by	the	time	the	mice	are	fifteen-months	old.	The	dysbiosis	was	associated	with	an	increase	in	diversity	in	the	mucosal	associated	microbiota	of	three-month	mice,	and	a	reduction	in	the	phylum	Firmicutes	in	seven-month	APP/PS1	mice.			An	increase	in	diversity	at	three-months	may	have	resulted	in	the	increased	production	of	SCFAs,	which	increased	the	number	of	EEC’s	in	the	colon.	Although	we	did	not	differentiate	the	type	of	EEC	affected,	we	propose	mechanisms	of	both	L	cells	and	EC	cells.	An	increase	in	L	cells	would	increase	the	secretion	of	GLP-1	and	PYY	resulting	in	decreased	GI	transit,	promoting	the	growth	of	the	microbiota	resulting	in	dysbiosis.	An	increase	in	EC	cells	could	result	in	increased	secretion	of	5-HT	which	in	contrast	to	GLP-1	and	PPY,	may	cause	an	increase	in	intestinal.	Furthermore,	an	increase	in	colonic	crypt	depth	was	also	observed	in	the	three-month	APP/PS1	mice,	which	we	suggested	could	be	due	to	a	dysbiosis	induced	increase	in	SCFA	which	inhibits	proliferation	of	stem	cells	at	the	base	of	the	crypts.			Seven-month	APP/PS1	mice	displayed	no	difference	in	diversity	of	the	microbiota	however	exhibited	a	decrease	in	the	phylum	Firmicutes.	Since	several	of	the	important	butyrate	producers	are	within	the	Firmicutes	phylum	we	
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suggest	this	may	have	resulted	in	the	decrease	in	EEC	numbers	observed	in	the	colon.				At	fifteen-months	there	was	no	observed	gut	dysbiosis,	however	there	was	a	decrease	in	goblet	cell	numbers	in	the	villi	and	crypts	of	the	ileum.	We	propose	this	is	due	to	the	downstream	consequences	enhanced	by	dysbiosis,	such	as	insulin	resistance.	We	predict	the	decrease	in	goblet	cells	is	able	to	exacerbate	the	pathology	by	decreasing	the	distance	between	the	microbiota	and	the	leaky	epithelial	barrier,	allowing	enhanced	translocation	of	the	microbiota	and	metabolites	across	the	barrier.			Furthermore,	we	propose	that	dysbiosis	occurs	in	the	large	intestine	drives	changes	in	the	architecture,	EEC	and	goblet	cell	numbers,	which	exacerbate	the	dysfunction	of	the	GBA	further.	GBA	dysfunction	in	addition	to	a	genetic	predisposition	through	the	possession	of	the	ApoE4	allele	is	the	trigger	in	initiating	AD	pathology.	As	the	AD	progresses	the	dysbiosis	begins	to	recover,	however	the	long-term	impact	of	GBA	dysfunction	including:	leaky	tight	junctions,	inflammation	and	insulin	resistance	continues	to	exacerbate	the	pathology.	Furthermore,	we	propose	that	altering	life	style	factors	such	as:	Western	diet,	antibiotic	use	and	prolonged	hospital	stays	may	perpetuate	the	gut	microbiota	further.			The	implications	for	this	research	lie	with	the	possibility	of	identifying	a	mucosal-associated	microbiota	profile	that	predicts	the	likelihood	of	an	individual	developing	AD.	Individuals	who	are	at	risk	and	those	who	are	in	the	early	stages	of	AD	could	have	their	microbiota	altered	to	one	that	is	associated	with	a	lower	risk	through	the	administration	of	probiotics	and	adopting	life	style	changes	such	as	a	Mediterranean	diet.	At	present,	with	the	absence	of	an	effective	treatment	and	no	cure,	this	seems	like	a	highly	plausible	diagnostic	and	therapeutic	tool	that	could	drastically	decrease	the	prevalence	of	AD	and	improve	the	lives	of	millions	of	people	worldwide.				
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